Insider Buying: Vital Therapies, Inc. (VTL) Director Acquires $40,000.00 in Stock

Vital Therapies, Inc. (NASDAQ:VTL) Director Jean Jacques Bienaime acquired 10,000 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was acquired at an average price of $4.00 per share, with a total value of $40,000.00. Following the transaction, the director now owns 65,119 shares in the company, valued at approximately $260,476. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vital Therapies, Inc. (NASDAQ VTL) traded up 5.88% during midday trading on Friday, hitting $4.50. The stock had a trading volume of 587,555 shares. The company’s market capitalization is $189.93 million. The company’s 50-day moving average price is $3.06 and its 200 day moving average price is $3.36. Vital Therapies, Inc. has a 52 week low of $2.25 and a 52 week high of $6.58.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. During the same period last year, the company posted ($0.30) earnings per share. On average, analysts expect that Vital Therapies, Inc. will post ($1.31) EPS for the current year.

WARNING: “Insider Buying: Vital Therapies, Inc. (VTL) Director Acquires $40,000.00 in Stock” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/09/17/insider-buying-vital-therapies-inc-vtl-director-acquires-40000-00-in-stock.html.

Separately, ValuEngine downgraded Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $8.00.

Several hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new stake in shares of Vital Therapies in the 2nd quarter valued at $268,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vital Therapies by 261.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after purchasing an additional 168,705 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Vital Therapies by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after purchasing an additional 29,840 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Vital Therapies by 67.2% in the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after purchasing an additional 40,000 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Vital Therapies in the 2nd quarter valued at $396,000. 25.58% of the stock is currently owned by hedge funds and other institutional investors.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply